ALR Technologies SG Ltd has announced a definitive manufacturing agreement with CGM Medical Technology Shen Zhen Ltd to produce the hardware for its GluCurve Pet Continuous Glucose Monitor (CGM). This agreement grants ALR Technologies exclusive global distribution rights for the CGM hardware in the animal health market. The first commercial shipment is expected in the third quarter of 2025.
The collaboration marks a significant step for ALR Technologies in expanding its footprint in the diabetes management sector. Sidney Chan, chairman and CEO of ALR Technologies, stated, “We have been collaborating with CGM Medical to develop the first large-scale manufacturing line for the CGM units that will be part of the ALRT GluCurve Pet CGM.” The company plans to enter a joint venture with CGM Medical to establish a fully automated manufacturing facility in Singapore, enhancing production efficiency and reducing costs.
This manufacturing agreement is part of ALR Technologies’ broader strategy to become a fully integrated player in the diabetes market. The company has been actively working on human health initiatives and has attracted interest from third parties for potential investments and commercial opportunities.
CGM Medical, known for its innovative medical device technology, focuses on developing accurate and affordable continuous glucose monitoring devices. The partnership with ALR Technologies is expected to leverage CGM Medical’s expertise in research and manufacturing to deliver effective solutions for diabetic care in pets.
The agreement is contingent upon the CGM hardware meeting ALR Technologies’ specifications, with future plans hinging on successful sample testing and production thresholds.
“`
